King subsidiary agrees to $42.5M settlement
The U.S. Justice Department says a subsidiary of Bristol, Tenn.-based King Pharmaceuticals Inc. has agreed to pay $42.5 million to settle allegations over the marketing of a painkiller.
Prosecutors announced the settlement on Tuesday with Alpharma Inc., which was bought by King in 2008, in a whistleblower lawsuit.
The lawsuit claimed Alpharma paid health care providers to induce them to promote or prescribe the morphine-based painkiller Kadian and made misrepresentations about the safety and efficacy of the drug.
The settlement will be split between the federal government and various states and was a collaboration between the Justice Department and the U.S. attorney's office in Maryland.
A message left for a spokesman for King was not immediately returned Tuesday afternoon.